190 related articles for article (PubMed ID: 2464794)
41. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.
Molica S; De Rossi G; Luciani M; Levato D
Haematologica; 1995; 80(2):176-93. PubMed ID: 7628755
[TBL] [Abstract][Full Text] [Related]
42. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
[TBL] [Abstract][Full Text] [Related]
43. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
44. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.
Schilling PJ; Vadhan-Raj S
N Engl J Med; 1990 Sep; 323(12):833-4. PubMed ID: 1697401
[No Abstract] [Full Text] [Related]
45. [The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
Gershanovich ML; Zaritskiĭ AIu; Medvedeva NV; Abdulkadyrov KM; Samuskevich IG; Beresneva IA
Vopr Onkol; 1998; 44(6):696-700. PubMed ID: 10087967
[TBL] [Abstract][Full Text] [Related]
46. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
47. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
[TBL] [Abstract][Full Text] [Related]
48. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
Hochster H; Cassileth P
Semin Oncol; 1990 Oct; 17(5 Suppl 8):63-5. PubMed ID: 1699284
[TBL] [Abstract][Full Text] [Related]
49. Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas.
Pazdur R; Samson MK; Baker LH
Am J Clin Oncol; 1987 Aug; 10(4):341-3. PubMed ID: 2441592
[TBL] [Abstract][Full Text] [Related]
50. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
Warrell RP; Berman E
J Clin Oncol; 1986 Jan; 4(1):74-9. PubMed ID: 2416889
[TBL] [Abstract][Full Text] [Related]
51. Phase II trial of fludarabine in patients with epithelial ovarian cancer.
Kavanagh JJ; Stringer CA; Copeland LJ; Gershenson DM; Saul P
Cancer Treat Rep; 1986 Mar; 70(3):425-6. PubMed ID: 2420446
[No Abstract] [Full Text] [Related]
52. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
[TBL] [Abstract][Full Text] [Related]
53. Chronic lymphocytic leukemia--correlation of response and survival.
Keating MJ; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Leuk Lymphoma; 1993; 11 Suppl 2():167-75. PubMed ID: 8124227
[TBL] [Abstract][Full Text] [Related]
54. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
Robertson LE; Huh YO; Butler JJ; Pugh WC; Hirsch-Ginsberg C; Stass S; Kantarjian H; Keating MJ
Blood; 1992 Jul; 80(1):29-36. PubMed ID: 1377051
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
Balducci L; Blumenstein B; Von Hoff DD; Davis M; Hynes HE; Bukowski RM; Crawford ED
Cancer Treat Rep; 1987 May; 71(5):543-4. PubMed ID: 2436773
[No Abstract] [Full Text] [Related]
56. Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Whelan JS; Davis CL; Rule S; Ranson M; Smith OP; Mehta AB; Catovsky D; Rohatiner AZ; Lister TA
Br J Cancer; 1991 Jul; 64(1):120-3. PubMed ID: 1713049
[TBL] [Abstract][Full Text] [Related]
57. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
Shevrin DH; Lad TE; Kilton LJ; Cobleigh MA; Blough RR; Weidner LL; Vogelzang NJ
Invest New Drugs; 1989 Jul; 7(2-3):251-3. PubMed ID: 2477345
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.
Ajani JA; Abbruzzese JL; Faintuch JS; Blackburn R; Levin B; Boman BM
Invest New Drugs; 1988 Apr; 6(1):47-50. PubMed ID: 2457566
[TBL] [Abstract][Full Text] [Related]
59. Fludarabine phosphate: an effective therapy for lymphoid malignancies.
Semin Oncol; 1990 Oct; 17(5 Suppl 8):1-78. PubMed ID: 1699278
[No Abstract] [Full Text] [Related]
60. Phase I study of fludarabine (2-fluoro-ara-AMP).
Kavanagh JJ; Krakoff IH; Bodey GP
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
